A Study of Volociximab in Metastatic Melanoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mihail Obrocea, MD
Abbott
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Site Reference Id/investigator# 70357
Scottsdale, Arizona, United States
- Site Reference Id/investigator# 70356
La Jolla, California, United States
- Site Reference Id/investigator# 70375
Aurora, Colorado, United States
- Site Reference Id/investigator# 70376
Boston, Massachusetts, United States
- Site Reference Id/investigator# 70359
St Louis, Missouri, United States
- Site Reference Id/investigator# 70380
Greenville, South Carolina, United States
- Site Reference Id/investigator# 70377
Dallas, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2006
- Primary completion
- 31 Mar 2008
- Completion
- 31 Mar 2008
- Last update posted
- 27 Apr 2012
- Registered enrollment
- 19
- Registry id
- NCT00369395
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.